β The Neos Therapeutics Board of Directors recommend stockholders vote βFORβ the transaction in advance of the virtual special meeting scheduled for MarchΒ 18, 2021 at 10:00 a.m. Eastern Time β β...
β The Neos Therapeutics Board of Directors recommend stockholders vote βFORβ the transaction in advance of the virtual special meeting scheduled for MarchΒ 18, 2021 at 10:00 a.m. Eastern Time β β...
β Record date for each Special Meeting of Stockholders is February 5, 2021 β β Upon merger closing, combined company will be renamed Aytu Biopharma, Inc. β ENGLEWOOD, Colo. and GRAND PRAIRIE...
DALLAS and FORT WORTH, Texas, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company developing and manufacturing central nervous...
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Neos Therapeutics, Inc. PR Newswire NEW YORK, Dec. 10, 2020 NEW YORK, Dec. 10, 2020 /PRNewswire/ -- Rowley Law PLLC is...
Merger accelerates transformation to profitability, with estimated annualized cost synergies of $15M beginning FY 2022Β Aytu adds Neosβ established, multi-brand ADHD portfolio, enhancing Aytuβs...
DALLAS and FORT WORTH, Texas, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company developing and manufacturing central nervous...
DALLAS and FORT WORTH, Texas, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company developing and manufacturing central nervous...
DALLAS and FORT WORTH, Texas, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company developing and manufacturing central nervous...
DALLAS and FORT WORTH, Texas, Aug. 10, 2020 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company developing and manufacturing central nervous...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.